Skip to main content
. 2017 Dec 27;2017:4384823. doi: 10.1155/2017/4384823

Table 3.

Clinicopathological characteristics of gastric cancer associated with CD44 expression (univariate Cox regression model analysis).

Clinicopathological characteristics of gastric cancer (n = 62) Expression of CD 44 protein (%) OR (95% CI) p value
Negative Positive
Location of tumor (%)
 (i) Upper 5.12 10.25 0.62 (0.48–0.87) 0.724
  (ii) Middle 10.25 15.38 0.87 (0.64–1.09) 0.953
  (iii) Lower 7.69 58.84 4.69 (2.01–6.48) 0.014
Tumor size (%)
 (i) ≥70 mm 7.69 48.71 5.74 (3.18–8.29) 0.019
 (ii) ≤70 mm 20.51 23.07 0.54 (0.42–0.76) 0.834
Histologic type (%)
 (i) Differentiated 23.07 17.94 0.73 (0.59–0.92) 0.524
 (ii) Undifferentiated 5.12 53.84 8.29 (6.38–12.19) 0.014
Lymphatic invasion (%)
  (i) Absent 41.02 7.69 4.21 (1.29–7.74) 0.028
  (ii) Present 12.82 38.46 3.39 (1.69–5.58) 0.032
Vascular invasion (%)
  (i) Absent 30.76 20.51 0.79 (0.62–1.38) 0.497
  (ii) Present 25.64 23.07 0.59 (0.42–1.18) 0.326
Pathological T stage (%)
  (i) T1-T2 30.76 28.20 0.82 (0.63–1.13) 0.284
  (ii) T3-T4 20.51 46.15 2.19 (1.02–6.29) 0.039
Pathological TNM stage (%)
  (i) I 7.69 5.12 0.92 (0.76–1.32) 0.562
  (ii) II 17.97 12.82 0.72 (0.51–1.15) 0.481
  (iii) III 5.12 28.02 4.49 (1.12–7.84) 0.010
  (iv) IV 2.56 20.51 3.32 (1.45–5.890) 0.029
Residual tumor [n = 29] (%)
  (i) No 58.97 15.38 2.89 (1.07–4.69) 0.039
  (ii) Microscopic 2.56 10.25 1.54 (1.01–4.43) 0.041
  (iii) Gross (unresectable) 5.12 7.69 0.74 (0.53–0.91) 0.624
CEA (%)
 (i) <5.0 (ng/ml) 28.02 33.33 0.69 (0.58–1.42) 0.573
 (ii) ≥5.0 (ng/ml) 17.94 20.51 0.98 (0.75–1.54) 0.782
5 years survival
(available n = 149) (%)
55.03 14.76 2.83 (1.98–5.62) 0.028

Univariate Cox regression model analysis used to analyze the data. OR, odds ratio; CI, confidence interval. Significance is set at p < 0.05.